• Seth Fagbemi MD

  • Physician - Hematology/Oncology


    • Oncology
    • 1000 North Oak Avenue 3A3 Marshfield, WI 54449
    • (715) 387-5416

Education


1998:
Fellowship, Hematology/Oncology, University of Chicago Hospitals, Chicago, IL
1995:
Residency, Chief Resident - Internal Medicine, Cook County Hospital, Chicago, IL
1995:
Residency, Internal Medicine, Cook County Hospital, Chicago, IL
1991:
Residency, Internal Medicine, University College Hospital, Ibadan, Nigeria
1990:
Fellowship, Part I, West African College of Physicians
1985:
Fellowship, Primary Fellowship, West African College of Physicians
1985:
Fellowship, Primary Fellowship, Nigerian Medical College of Physicians
1985:
Fellowship, Primary Fellowship, Nigerian Medical College of General Medical Practitioners
1982:
MB BS, Medicine, University of Ibadan, Ibadan Nigeria

Work Experience


2002 to Present:
Oncologist/Hematologist, Marshfield Clinic, Inc. - Marshfield Center, Marshfield, WI
2002 to Present:
Oncologist/Hematologist, Marshfield Clinic, Inc. - Wisconsin Rapids Center, Wisconsin Rapids, WI
2002 to Present:
Attending Physician, Marshfield Medical Center - Marshfield, Marshfield, WI
1999 to 2002:
Physician - Internal Medicine, Professional Medical Center, Detroit, MI
1989 to 1991:
Senior House Officer - Registrar, University College Hospital, Ibadan, Nigeria
1986 to 1989:
Medical Officer, NAF Medical Center, Kano, Nigeria
1984 to 1985:
Medical Officer, State Hospital, Owo, Nigeria
1983 to 1984:
Medical Officer (NYSC), District Health Unit, Offa, Nigeria
1982 to 1983:
House Officer, State Hospital, Akure, Nigeria

Board Certifications


1995 to 2005:
American Board of Internal Medicine - Internal Medicine
2001 to 2021:
American Board of Internal Medicine - Medical Oncology (2001), Recertified 2011
2003 to 2023:
American Board of Internal Medicine - Hematology (2003), Recertified 2013

Select Publications


  • Fagbemi SO, Stadler WM. (1997). New molecules and regimens. Adjuvant Treatment in Urological Cancer. :261-271.
  • Fagbemi SO, Lyer L. (1997). Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA). Proceedings of the American Society of Clinical Oncology.
  • Fagbemi SO, Stadler WM. (1998 February). New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 16(1):23-29.
    PubMed ID: 9508079
  • Onitilo AA, Engel JM, Olatosi B, Fagbemi SO. (2007 July). Community experience with bortezomib in patients with multiple myeloma. Am J Hematol. 82(7):637-639.
    PubMed ID: 17301970